Meeting Summary - PCWP/HCPWP joint meeting

Human medicines European public assessment report (EPAR): Wyost, denosumab, Date of authorisation: 17/05/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Mepsevii, vestronidase alfa, Date of authorisation: 23/08/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Altuvoct, efanesoctocog alfa, Date of authorisation: 17/06/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Tolura, telmisartan, Date of authorisation: 04/06/2010, Revision: 15, Status: Authorised

EMA risk management information day

Clinical Trial Information System (CTIS) - Sponsor handbook

Working arrangement for the collaboration and exchange of information on therapeutic products and medicinal products between DG SANTE/EMA and the New Zealand Ministry of Health

Orphan designation: copper metabolism disorder Treatment of Wilson's disease, 20/05/2026 Positive

Orphan designation: alixorexton Treatment of narcolepsy, 20/05/2026 Positive